JonesResearch initiated coverage of CG Oncology (CGON) with a Buy rating and $50 price target The late-stage company is developing an oncolytic virus, cretostimogene grenadenorepvec, in multiple settings of Non-Muscle Invasive Bladder Cancer, notes the analyst, who calls CG “a good bet in the bladder cancer space” with a strong cash position to fund several of trials through regulatory filings and “a fairly derisked drug with potentially best-in-class efficacy.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Buy Rating for CG Oncology: Promising NMIBC Treatment and Strong Financial Position
- Buy Rating for CG Oncology, Inc.: Promising Data on Creto’s Efficacy and Safety in NMIBC Treatment
- CG Oncology’s Promising Clinical Results and Strategic Positioning Drive Buy Rating
- Promising Phase 3 Results for CG Oncology’s Cretostimogene Highlight Competitive Edge in Bladder Cancer Treatment
- Promising Outlook for CG Oncology, Inc.: Buy Rating Supported by Cretostimogene’s Efficacy and Market Potential